Special Issue "Active Pharmaceutical Ingredients"
A special issue of Molecules (ISSN 1420-3049).
Deadline for manuscript submissions: closed (31 January 2013)
Prof. Dr. Cody P. Coyne
Department of Basic Sciences, College of Veterinary Medicine at Wise Center, Mississippi State University, State, MS 39762-6100, USA
Phone: +662 325 1120
Interests: pharmaceutical molecular design; selectively “targeted” pharmaceutical delivery; organic chemistry synthesis schemes; alternative pharmaceutical efficacies; additive and synergistic pharmaceutical combinations; diagnostic pharmaceuticals.
In the field of pharmacology, the spectrum of different molecular platforms that possess biological activity that impart therapeutic and diagnostic properties has markedly expanded since the early development of sulfonamide dyes as anti-bacterial agents. Besides classical small molecular weight pharmaceuticals the range of clinically relevant therapeutics now includes hormone analogs (agonists and antagonists), monoclonal immunoglobulin (e.g. anti-HER2/neu, anti-EGFR), receptor ligands, biologically active peptides (e.g. IL-2), conjugated preparations, photodynamic agents (e.g. 5-aminolevulinic acid), gene therapies (e.g. anti-sense mRNA), diagnostic dyes (e.g. methylene blue), and diagnostic imaging agents (18F-glucose), diagnostic function/response (e.g. dexamethazone, albuterol), and herbal preparations (e.g. arnica, aloe vera, ginsing). A quality that almost invariably all molecular based modalities share in common is at least one chemically active site that is responsible for their mechanism-of-action and a biological effect that is therapeutically relevant. Rarely small molecular weight pharmaceuticals like digitoxin exert multiple mechanisms-of-action which is a property that is often more frequently be seen with large molecular weight therapeutics which contain multiple different moieties where each one has a unique chemically active or biologically active site capable of evoking their own individual mechanism-of-action and biological effect (e.g. Glembatumumab vedotin, epirubicin-[anti-HER2/neu]). This special issue of Molecules welcomes previously unpublished manuscripts covering aspects about therapeutic agents pertaining to the first-time discovery or characterization of chemically active sites related to their mechanism-of-action, biological activity, physiological effect or therapeutic properties.
Prof. Dr. Cody P. Coyne
Related Special Issues in Other Journals
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed Open Access monthly journal published by MDPI.
- chemically active site or moiety
- biologically active site or moiety
Molecules 2012, 17(10), 11990-12002; doi:10.3390/molecules171011990
Received: 3 September 2012; in revised form: 28 September 2012 / Accepted: 8 October 2012 / Published: 12 October 2012| Download PDF Full-text (634 KB) | Download XML Full-text
Last update: 4 February 2013